Related to Novartis to License Phase II Anticlotting Therapy from Portola for $75M

• Beckman Coulter to Pay Clinical Data $17M for Genomic Services Division
  
• ImmuneRegen Allies with University of Rochester to Expand Preclinical Development of Homspera
  
• Cordex Taps BG Medicine to Advance Its Early-Stage Heart Failure Drug
  
• Merck & Co. Buys Rights to Atrial Fibrillation Therapy from Cardiome for $60M Up Front
  
• LDL-Controlling Protein Exerts Effect Extracellularly
  
• Clarient Acquires Breast Cancer Biomarker from Indiana University
  
• Role of COMT Gene Mutation in Post Heart Surgery Complications Revealed
  
• The Medicines Company Axes Phase III Percutaneous Coronary Intervention Program
  
• Novartis to Buy EBEWE Pharma’s Generics Business for $1.2B
  
• Preliminary Phase III Data Is Positive for Novartis’ COPD Drug
  
• Amgen Obtains Cardiovascular Program for $50M from Cytokinetics
  
• Novartis Offers 28% More for Increased Control over India Operations
  
• Novartis' Osteoporosis Drug Gets FDA Okay for Preventing Postmenopausal Osteoporosis
  
• Novartis Vaccines Institute Gets Roughly $7M to Develop Bivalent Typhoid Vaccine
  
• Roche, SeqWright, and Miller School of Medicine in Search of Genetic Causes of Dilated Cardiomyopathy
  
• NHLBI and UnitedHealth Join Forces to Create Research Centers for Chronic Diseases in Developing Countries
  
• Novartis Gets FDA Okay for Drug to Treat Rare Inflammatory Disorder
  
• Israeli Government Boosts Compugen Drug Discovery Funding with $400K
  
• EU Sanctions Novartis Drug for Steroid-Induced Osteoporosis
  
• Vectura and Sosei Receive $7.5M Each with Start of Phase III COPD Trial by Novartis